NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) announced today that its PGxHealth™ division, provider of Therapeutic Diagnostics™, will present data on the confirmation of a genetic marker associated with clozapine-induced agranulocytosis (CIA) at the International Congress on Schizophrenia Research (ICOSR) to be held March 28 through April 1, 2007, in Colorado Springs, CO. CIA is a rare but serious side effect of clozapine, an antipsychotic indicated for treatment-resistant schizophrenia.
